The present disclosure relates to the field of immunology, in particular to a B-cell epitope of Trichinella spiralis cysteine protease inhibitor, a hybridoma cell line, a monoclonal antibody and uses thereof. The present disclosure provides a hybridoma cell line that can generate anti-WN10 antibody, and identifies the specific B-cell epitope of WN10 protein recognized by the monoclonal antibody. These are of great significance for the diagnosis of trichinellosis, for the establishment of competitive ELISA for detecting antibodies and sandwich ELSIA for detecting circulating antigens, for the detection of Trichinella spiralis in different hosts and for the development of subunit vaccines.

A method of generating an antibody and cellular immune response against a Plasmodium in a primate, comprising administering at least 10.sup.3 genetically modified live Plasmodium to the primate, wherein the genetically modified live Plasmodium is a species selected from Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale, Plasmodium malariae, Plasmodium knowlesi, Plasmodium coatneyi, Plasmodium cynomolgi, and Plasmodium simium, and wherein the genetically modified live Plasmodium does not produce functional histamine releasing factor (HRF) protein, to thereby induce an antibody and cellular immune response against the Plasmodium in the primate. In some embodiments at least 10.sup.4 genetically modified live Plasmodium is administered to the primate. An immunogenic composition for administration to a primate, comprising a at least 10.sup.3 genetically modified live Plasmodium wherein the genetically modified live Plasmodium is a species selected from Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale, Plasmodium malariae, Plasmodium knowlesi, Plasmodium coatneyi, Plasmodium cynomolgi, and Plasmodium simium, and wherein the genetically modified live Plasmodium does not produce functional histamine releasing factor (HRF) protein; and at least one pharmaceutically acceptable excipient and/or support. In some embodiments the immunogenic composition comprises at least 10.sup.3 genetically a modified live Plasmodium.

Provided herein are Purine Comounds of Formula (I)

##STR00001## or pharmaceutically acceptable salts, tautomers, isotopologues, or stereoisomers thereof, wherein R.sup.1, R.sup.2, and R.sup.3 are as defined herein, compositions comprising an effective amount of a Purine Compound, and methods for treating or preventing malaria comprising the administration of an effective amount of a Purine Compound.

Provided herein are Aminopurine compounds of Formula I:

##STR00001## or pharmaceutically acceptable salts, tautomers, isotopologues, or stereoisomers thereof, wherein R.sup.1, R.sup.2, and R.sup.3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound, and methods for treating or preventing animal and human protozoal infections.

A system and method for detecting pathogenetic analytes including exciting a large target input area with radiation to produce scattered light to form an input beam, reformatting, with an optical slicer system, the input beam to produce an output beam, dispersing the output beam to produce an output area, capturing excitation data from the output area; and determining, with a processor, a presence of a particular analyte in the input area based on the excitation data. The input area can be greater than 100 micron squared and less than one million microns squared. The optical slicer system can be a high throughput virtual slit system. SERS analysis detects analytes of interest with both high resolution and sensitivity simultaneously, and is applicable for detection of the presence of viruses.

The presence of hemozoin as an indicator of malaria in a blood sample is detected by magnetic separation, dissolution and spectroscopic analysis.

Certain embodiments are directed to method for synthesizing and using glycoconjugates on the immunodominant epitope Galα(1,3)Galβ(3(1,4)GlcNAcα (Galα3LNα).

The invention provides a bioactive peptide including a partial amino acid sequence of Plasmodium falciparum enolase, and having a molecular structure compatible with a specification setting for a GMP-compliant production process. The peptide has a structure in which two peptides, each having an amino acid sequence of A01-Ala-Ser-Glu-Phe-Tyr-Asn-Ser-Glu-Asn-Lys-Thr-Tyr-Asp-Leu-Asp-Phe-Lys-Thr-Pro-Asn-Asn-Asp-A02 (SEQ ID NO: 1) or A03-Ala-Ser-Glu-Phe-Tyr-Asn-Ser-Glu-Asn-Lys-Thr-Tyr-Asp-Leu-Asp-Phe-Lys-Thr-Pro-Asn-Asn-Asp-Lys-Ser-Leu-Val-Lys-Thr-A04 (SEQ ID NO: 2) are linked by amide bonds between the respective carboxy termini of the two peptides and two amino groups of Lys in a linker peptide represented by Lys-A05-Cys-A06 and arranged in the form of a two-forked branch, wherein each of A01 to A06 represents an amino acid residue in a number of an arbitrary number including 0. The peptide preferably has a dimerized structure in which two of the above described peptides are linked by an S—S bond between the Cys residues in the linker peptide sequences included in the respective two peptides.

The present invention relates to the synthesis of GPI-related surface antigens of the parasite Toxoplasma gondii (T. gondii) and the resulting products obtained. These synthetic compounds are suitable for diagnosis of toxoplasmosis, as well as vaccine against toxoplasmosis, a diseases caused by infection with T. gondii.

The present invention relates to peptides and methods for the detection of anti-leishmanial antibodies in individuals suspected of infection with the protozoan parasite of the genus Leishmania, especially infection with a South American strain causing the American Tegumentary Leishmaniasis (ATL).